Navigation Links
VirtualScopics Schedules First Quarter 2009 Earnings Announcement
Date:4/22/2009

ROCHESTER, N.Y., April 22 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, today announced that on Tuesday, May 5, 2009 it will release its first quarter 2009 financial results. The company will host a conference call to discuss these results on Wednesday, May 6, 2009 at 11:00 a.m. EDT.

VirtualScopics' President and Chief Executive Officer, Jeff Markin, and Chief Business and Financial Officer, Molly Henderson, will provide a business update and discuss the company's results for the quarter ended March 31, 2009 during the conference call.

Interested participants should call 877-407-8031 when calling within the United States or 201-689-8031 when calling internationally. There will be a playback available until June 7, 2009. To listen to the playback, please call 877-660-6853 when calling within the United States or 201-612-7415 when calling internationally. For the replay, please use account number: 286, conference ID number: 320761.

This call can also be accessed at www.virtualscopics.com and will be available for 30 days after the call.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the backlog and new customer awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to awards of contracts currently under negotiation, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

    CONTACT:      Molly Henderson
                  Chief Business and Financial Officer
                  500 Linden Oaks
                  Rochester, New York 14625
                  (585) 249.6231


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. VirtualScopics Scientists to Present at International Society for Magnetic Resonance in Medicine 17th Scientific Meeting and Exhibition
2. VirtualScopics Receives Further Extension to Regain Compliance With Nasdaq
3. VirtualScopics to Present at 11th Annual BIO CEO & Investor Conference
4. VirtualScopics Backlog Rises to a Record $27 Million
5. VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit
6. VirtualScopics to Present at Two Upcoming Investor Conferences
7. VirtualScopics Schedules Third Quarter 2008 Earnings Announcement
8. VirtualScopics Reports Second Quarter 2008 Results
9. VirtualScopics Receives NASDAQ Delisting Notice; Company Files Appeal to Stay Delisting
10. VirtualScopics Backlog Exceeds a Record $20 Million
11. VirtualScopics Announces $4.35 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... "ProDOF is the perfect set of tools for video editors ... in a scene," said Christina Austin - CEO of Pixel Film Studios. , Video ... create the illusion of a DSLR racking focus from one area into the next. ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual ... alumni, family, friends, and community. “Coming Home 2017” will be held on ...
(Date:1/21/2017)... ... 2017 , ... In the United States, 20 million women and 10 million ... often feel shame for having struggled with an eating disorder as well as common ... Strong in Life After an Eating Disorder” -- to be featured at this year’s ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between ... they no longer use or need, from clothes to couches to dressers and bicycles. ... and take them to the nearest Goodwill donation center through February 28th. , ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company based out of ... show to continue the marketing and distribution of its product, The Right C. , ... percent better absorption than traditional vitamin C supplements. At the trade show, Doctor C ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ... mitochondrial dysfunction, today announced new additions to its senior ... Chief Medical Officer, and Daniel Geffken as ... Jim Carr , Pharm.D. has been promoted to ... pleased to welcome Doug and Daniel to our management ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
(Date:1/19/2017)... January 19, 2017 Pfizer ... the Milner Therapeutics Consortium   Major ... Cambridge   The Milner ... PFE ) as a partner to the Milner Therapeutics ... enables the efficient transfer of materials between industry and ...
Breaking Medicine Technology: